Personalized medicine in RA
| Reference number | |
| Coordinator | Karolinska Institutet - Institutionen för Medicin |
| Funding from Vinnova | SEK 20 824 869 |
| Project duration | April 2019 - April 2022 |
| Status | Ongoing |
| Venture | Nordiskt samarbete inom hälsa |
Purpose and goal
Rheumatoid arthritis (RA) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that accounts for ~10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality. Our aim is to develop a personalized medicine approach to the management of RA by the development of new prediction tools and by digital tools to bring these new insights to patients and health-care.
Expected results and effects
The expected results from the NORA project are a better and earlier treatment of RA in combination with product development (for diagnostics and digital health tools) that can be used for cost-effective improvement of treatment results for patients and thereby become attractive commercial products.
Planned approach and implementation
Our approach builds on our strong collaboration within Nordic Rheumatology, and a complementary public-private partner constellation that spans all the necessary competences and infrastructures. The novelty in our approach includes the availability and analyses of data across different domains (genomics, biomarkers, clinical data, patient-reported data, register-linkage data) that so far have not been analyzed together, new biomarker assays, the inclusion of patient-centric outcomes (e.g., pain) rather than composite and insensitive outcome metrics.